Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neurosurg Clin N Am ; 33(3): 305-309, 2022 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-35718400

RESUMO

Intrathecal pumps deliver analgesic medication directly into the central nervous system. In patients with chronic nonmalignant pain, intrathecal therapy using morphine or ziconotide has been shown to be an effective option when traditional noninvasive methods do not provide adequate relief. There has been increasing use of intrathecal drug administration in the management of patients with nonmalignant pain in recent years given the advances in technology and research on the topic. However, due to its invasive nature, intrathecal pumps remain the last option among patients with chronic pain.


Assuntos
Dor Crônica , ômega-Conotoxinas , Analgésicos/uso terapêutico , Analgésicos Opioides/uso terapêutico , Dor Crônica/tratamento farmacológico , Humanos , Bombas de Infusão Implantáveis , Injeções Espinhais , Morfina/uso terapêutico , Medição da Dor
2.
J Invest Dermatol ; 142(6): 1523-1528.e1, 2022 06.
Artigo em Inglês | MEDLINE | ID: mdl-35598899

RESUMO

In various diseases, particularly cancer, cell-free DNA (cfDNA) has been widely studied as a marker of disease prognosis or to facilitate the detection of therapeutic targets. In dermatology, most studies have focused on melanoma; other skin diseases such as vascular malformations and psoriasis have also been examined. Genetic alterations unique to the tissue of origin such as sequence variations, copy number alterations, chromosomal rearrangements, differential DNA methylation patterns, and fragmentation patterns can be identified in circulation providing information on patient disease status. These alterations can be detected either by PCR-based methods or next-generation sequencing depending on the target of interest. In this article, we discuss the origins of cfDNA, the most common methods of detection, current studies assessing cfDNA as a biomarker, and cfDNA's potential clinical applications in melanoma and other skin diseases. In addition, we provide important factors to consider during blood processing and DNA extraction as well as limitations for each assay.


Assuntos
Ácidos Nucleicos Livres , Dermatologia , Melanoma , Biomarcadores Tumorais/genética , Ácidos Nucleicos Livres/genética , Metilação de DNA , Sequenciamento de Nucleotídeos em Larga Escala/métodos , Humanos , Melanoma/diagnóstico , Melanoma/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...